Intent to Apply (ITA)
A total of 36 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below:

*One or more ITA included multiple diseases, interventions and/or development stages in the scope.
Full Proposal

A total of 25 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:

### Disease

- Malaria, 11
- TB, 4
- Leishmaniasis, 3
- Chagas disease, 5
- Trypanosomal diseases, 1
- Schistosomiasis, 1

### Intervention

- Drug, 19
- Vaccine, 6

### Development Stage

- Pre-clinical, 19
- Clinical, 6
Award Notification
The following six projects were awarded funding.

<table>
<thead>
<tr>
<th>Project Title</th>
<th>Collaboration Partners</th>
<th>Disease</th>
<th>Intervention</th>
<th>Development Stage</th>
<th>Total Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Development of recombinant hPIV2 virus vector as a new TB vaccine</td>
<td>1. National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN) 2. JBL 3. Aeras</td>
<td>TB</td>
<td>Vaccine</td>
<td>Pre-clinical</td>
<td>¥70,000,000</td>
</tr>
<tr>
<td>Clinical development of BK-SE36/CpG malaria vaccine</td>
<td>1. RIMD, Osaka University 2. Medical Center for Translational Research, Osaka University 3. Gulu University</td>
<td>Malaria</td>
<td>Vaccine</td>
<td>Clinical Ph 1</td>
<td>¥71,450,000</td>
</tr>
<tr>
<td>Optimization of Diversity-Oriented Synthesis (DOS)-derived trypanocidal small molecule ML341 towards investigational new drug status for Chagas disease.</td>
<td>1. Broad Institute 2. Eisai 3. NTD (Chagas disease)</td>
<td>NTD (Chagas disease)</td>
<td>Drug</td>
<td>Pre-clinical</td>
<td>¥50,000,000</td>
</tr>
<tr>
<td>Development of DSM265 as a long acting antimalarial compound</td>
<td>1. MMV 2. Takeda</td>
<td>Malaria</td>
<td>Drug</td>
<td>Clinical Ph 2</td>
<td>¥253,879,600</td>
</tr>
<tr>
<td>Development of ELQ300 as a long acting antimalarial</td>
<td>1. MMV 2. Takeda</td>
<td>Malaria</td>
<td>Drug</td>
<td>Pre-clinical</td>
<td>¥21,679,055</td>
</tr>
<tr>
<td>Accelerating Development of Vaccines for Malaria Elimination Using a Novel Clinical Target Validation Approach</td>
<td>1. PATH Malaria Vaccine Initiative 2. Ehime University 3. Cell Free Sciences</td>
<td>Malaria</td>
<td>Vaccine</td>
<td>Pre-clinical</td>
<td>¥59,139,656</td>
</tr>
</tbody>
</table>